Genprex announced that it received notices of allowance for patents from both the U.S. and European Patent Offices for its Reqorsa® Gene Therapy in combination with PD-L1 and PD-1 antibodies, with patents expiring in 2037. This development supports Genprex’s Acclaim-3 clinical trial for small cell lung cancer, which has received FDA Fast Track and Orphan Drug Designations, potentially enhancing the company’s market position and stakeholder confidence.
Genprex, Inc. operates in the biotechnology industry, focusing on developing gene therapies for cancer and diabetes. The company is known for its lead drug candidate, Reqorsa® Gene Therapy, which targets cancer treatment through innovative combinations with immunotherapy drugs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.